Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Profile

Rangaswamy Govindarajan

Concepts (127)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
161
0.810
 Why?
Anus Neoplasms
1
2018
24
0.620
 Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
989
0.540
 Why?
Bone Marrow Neoplasms
1
2015
13
0.530
 Why?
Embolism
1
2015
20
0.530
 Why?
Gene Regulatory Networks
1
2016
107
0.510
 Why?
Carcinoma, Squamous Cell
1
2018
318
0.510
 Why?
Tumor Lysis Syndrome
1
2014
6
0.500
 Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
55
0.480
 Why?
Neoplasm Recurrence, Local
1
2018
614
0.470
 Why?
Pyrazoles
1
2014
113
0.460
 Why?
Pyrimidines
1
2014
192
0.440
 Why?
Angiogenesis Inhibitors
2
2006
187
0.430
 Why?
Clinical Trials as Topic
5
2019
461
0.430
 Why?
Biliary Tract Diseases
1
2012
12
0.430
 Why?
Actinomycosis
1
2012
10
0.430
 Why?
Salvage Therapy
1
2013
139
0.420
 Why?
Stomach Neoplasms
1
2015
174
0.420
 Why?
Bile Duct Neoplasms
1
2012
29
0.420
 Why?
Prognosis
6
2019
1942
0.390
 Why?
Gene Expression Profiling
1
2016
1032
0.390
 Why?
Benzenesulfonates
2
2011
10
0.380
 Why?
Middle Aged
12
2020
12069
0.380
 Why?
Carcinoma, Hepatocellular
1
2013
191
0.370
 Why?
Stroke
1
2015
492
0.360
 Why?
Pyridines
2
2011
130
0.350
 Why?
Liver Neoplasms
1
2013
326
0.340
 Why?
Colorectal Neoplasms
2
2003
236
0.340
 Why?
Aged, 80 and over
6
2018
3129
0.300
 Why?
Heparin
1
2007
92
0.290
 Why?
Drug Industry
1
2007
38
0.290
 Why?
Thrombocytopenia
1
2007
85
0.280
 Why?
Communication Barriers
1
2007
33
0.280
 Why?
Hypertensive Encephalopathy
1
2006
3
0.280
 Why?
raf Kinases
1
2006
4
0.280
 Why?
Thiazolidinediones
1
2007
82
0.280
 Why?
Aged
9
2020
9310
0.260
 Why?
Anticoagulants
1
2007
250
0.250
 Why?
Thrombosis
1
2007
248
0.240
 Why?
Skin
1
2007
409
0.240
 Why?
Adult
9
2020
13236
0.240
 Why?
Enzyme Inhibitors
1
2006
391
0.240
 Why?
Female
11
2020
26472
0.230
 Why?
Survival Rate
2
2018
894
0.220
 Why?
Prostatic Neoplasms
1
2007
394
0.220
 Why?
Humans
16
2020
49974
0.220
 Why?
Follow-Up Studies
3
2019
2182
0.210
 Why?
Camptothecin
1
2002
16
0.210
 Why?
Male
10
2020
25241
0.210
 Why?
Antineoplastic Agents, Phytogenic
1
2002
69
0.200
 Why?
Lung Neoplasms
1
2007
606
0.190
 Why?
Diabetes Mellitus, Type 2
1
2007
477
0.190
 Why?
Oximes
1
2020
11
0.190
 Why?
Pyrimidinones
1
2020
17
0.190
 Why?
Pyridones
1
2020
34
0.180
 Why?
Imidazoles
1
2020
119
0.170
 Why?
Thalidomide
1
2002
377
0.170
 Why?
Cholangiocarcinoma
2
2011
26
0.170
 Why?
Protein Kinase Inhibitors
1
2020
204
0.160
 Why?
Survival Analysis
3
2020
653
0.150
 Why?
Antineoplastic Agents
2
2019
1171
0.150
 Why?
Melanoma
1
2020
285
0.140
 Why?
Neoplasm Staging
2
2013
740
0.140
 Why?
Combined Modality Therapy
1
2018
637
0.140
 Why?
Severity of Illness Index
1
2019
945
0.130
 Why?
Antibodies, Monoclonal
1
2019
459
0.130
 Why?
Skin Neoplasms
1
2020
488
0.130
 Why?
Gene Amplification
1
2015
57
0.120
 Why?
Adenine
1
2014
32
0.120
 Why?
Polycomb Repressive Complex 2
1
2015
47
0.120
 Why?
Genes, myc
1
2015
40
0.120
 Why?
Retrospective Studies
3
2018
6108
0.120
 Why?
United States
3
2019
4860
0.120
 Why?
Piperidines
1
2014
98
0.120
 Why?
Registries
3
2007
522
0.110
 Why?
Gene Deletion
1
2015
266
0.110
 Why?
Treatment Outcome
4
2020
5141
0.110
 Why?
Quinazolines
1
2013
33
0.110
 Why?
Leukemia, Myeloid, Acute
1
2015
185
0.110
 Why?
Actinomyces
1
2012
9
0.110
 Why?
Endoscopy, Gastrointestinal
1
2012
73
0.100
 Why?
Gene Expression Regulation, Neoplastic
1
2016
828
0.100
 Why?
Gallbladder Neoplasms
1
2011
5
0.100
 Why?
Comorbidity
2
2019
615
0.100
 Why?
Antibodies, Monoclonal, Humanized
1
2013
225
0.100
 Why?
Phenylurea Compounds
2
2011
15
0.100
 Why?
Niacinamide
2
2011
22
0.090
 Why?
Incidence
2
2019
1003
0.090
 Why?
Neoplasms
1
2019
1235
0.080
 Why?
Drugs, Investigational
1
2007
14
0.070
 Why?
Necrosis
1
2007
176
0.070
 Why?
Causality
1
2007
44
0.070
 Why?
Hospitals, University
1
2007
77
0.070
 Why?
Confidence Intervals
1
2007
156
0.070
 Why?
Neoplasm Metastasis
2
2011
231
0.070
 Why?
Tomography, X-Ray Computed
1
2012
1159
0.070
 Why?
Age Distribution
1
2007
168
0.070
 Why?
Probability
1
2007
164
0.070
 Why?
United States Food and Drug Administration
1
2007
93
0.070
 Why?
Anti-Bacterial Agents
1
2012
744
0.070
 Why?
Medical Oncology
1
2007
94
0.070
 Why?
Syndrome
1
2006
237
0.070
 Why?
Patient Selection
1
2007
253
0.060
 Why?
Publication Bias
1
2005
11
0.060
 Why?
Editorial Policies
1
2005
11
0.060
 Why?
Periodicals as Topic
1
2005
58
0.060
 Why?
Dose-Response Relationship, Drug
1
2007
1376
0.060
 Why?
Risk Assessment
1
2007
1259
0.050
 Why?
MAP Kinase Kinase Kinases
1
2020
19
0.050
 Why?
Socioeconomic Factors
1
2003
581
0.050
 Why?
Proto-Oncogene Proteins B-raf
1
2020
79
0.040
 Why?
Mutation, Missense
1
2020
105
0.040
 Why?
Drug Administration Schedule
1
2020
376
0.040
 Why?
Trisaccharides
1
2019
1
0.040
 Why?
Premedication
1
2019
21
0.040
 Why?
Administration, Oral
1
2020
426
0.040
 Why?
Magnetic Resonance Imaging
1
2006
1537
0.040
 Why?
Infusions, Intravenous
1
2019
206
0.040
 Why?
Antibodies
1
2019
154
0.040
 Why?
Health Services Accessibility
1
2003
398
0.040
 Why?
Disease Management
1
2019
174
0.040
 Why?
Arkansas
1
2003
1977
0.040
 Why?
Adolescent
1
2007
6356
0.030
 Why?
In Situ Hybridization, Fluorescence
1
2015
259
0.030
 Why?
Polymorphism, Single Nucleotide
1
2015
485
0.030
 Why?
Young Adult
1
2020
3958
0.020
 Why?
Disease-Free Survival
1
2011
454
0.020
 Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (127) concept(s)
_
Co-Authors Expand Description
See all (1) people
_
Similar People Expand Description
See all (32) people
_
Same Department Expand Description
Search Department